

# Gastroenterology

## Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis

--Manuscript Draft--

<b>Manuscript Number:</b>	GASTRO-D-16-01679R1
<b>Full Title:</b>	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
<b>Article Type:</b>	Solicited Reviews in Basic Clin. Gastro.
<b>Section/Category:</b>	Translational
<b>Keywords:</b>	Keywords: liver cancer, cell of origin, hepatocytes, stem cells, molecular classification, prognosis.
<b>Corresponding Author:</b>	Josep M Llovet, MD Liver Cancer Translational Research Laboratory Barcelona, SPAIN
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Liver Cancer Translational Research Laboratory
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Daniela Sia
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Daniela Sia Augusto Villanueva Scott L. Friedman Josep M Llovet, MD
<b>Order of Authors Secondary Information:</b>	
<b>Manuscript Region of Origin:</b>	UNITED STATES
<b>Abstract:</b>	<p>Primary liver cancer is the second leading cause of cancer-related death worldwide and therefore a major public health challenge. We review hypotheses of the cell of origin of liver tumorigenesis, and clarify the classes of liver cancer, based on molecular features and how these affect patient prognosis. Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare tumors, notably fibrolamellar carcinoma and hepatoblastoma. The molecular and clinical features of HCC vs iCCA are distinct, although they have overlapping risk factors and pathways of oncogenesis. A better understanding of the cell types originating liver cancer can aid in exploring molecular mechanisms of carcinogenesis and therapeutic options. Molecular studies have identified adult hepatocytes as the cell of origin. These cells have been proposed to transform directly into HCC cells (via a sequence of genetic alterations), to de-differentiate into hepatocyte precursor cells (which then become HCC cells that express progenitor cell markers), or to trans-differentiate into biliary-like cells (which give rise to iCCA). Alternatively, progenitor cells also give rise to HCCs and iCCAs with markers of progenitor cells. Advances in genome profiling and next-generation sequencing have led to the classification of HCCs based on molecular features, and assigned them to categories such as proliferation-progenitor, proliferation-transforming growth factor beta, and Wnt-catenin beta 1. iCCAs have been assigned to categories of proliferation and inflammation. Overall, proliferation subclasses are associated with a more aggressive phenotype and poor outcome of patients, although more specific signatures have refined our prognostic abilities. Analyses of genetic alterations have identified those that might be targeted therapeutically, such as fusions in the FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs) or amplifications at 11q13 and 6p21 (in approximately 30% of HCCs). Further studies of these alterations are needed before these can be used as biomarkers in clinical decision</p>

making.

**Title:** Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis

Daniela Sia<sup>1</sup>, Augusto Villanueva<sup>1</sup>, Scott L. Friedman<sup>1</sup> and Josep M. Llovet<sup>1,2,3</sup>

<sup>1</sup> Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Hematology and Medical Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.

<sup>2</sup> Liver Cancer Translational Research Laboratory, BCLC, Liver Unit, CIBEREHD, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain.

<sup>3</sup> Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

**Grant support:** DS is the recipient of the Andrea Marie Fuquay Memorial Research Fellowship (Cholangiocarcinoma Foundation). AV is the recipient of the American Association for the Study of Liver Diseases Foundation Alan Hofmann Clinical and Translational Award. SLF is supported by NIH grants DKRO156621 and AA. 020709. J.M.L. has grants from the US National Cancer Institute (NCI) (P30CA165979), the European Commission Horizon 2020 (HEP-CAR 667273–2), the Samuel Waxman Cancer Research Foundation, the Grant I+D Program (SAF2013-41027) and the Asociación Española Contra el Cáncer (AECC).

**Disclosures:** AV and JML are co-inventors of a patent: “Compositions, Kits, and methods for identification, assessment, prevention and therapy of hepatic disorders”.

**Total Word counts:** current 6543

**References:** current 176

**Tables:** 2

**Figures:** 5

**Address for correspondence:**

Josep M. Llovet, MD

Professor of Medicine

Mount Sinai Liver Cancer Program

Division of Liver Diseases

Icahn School of Medicine at Mount Sinai

1425 Madison Avenue, Box 11-23

New York 10029, NY

Phone: 1-2126599503

Fax: 212-849-2574

Email: [Josep.Llovet@mssm.edu](mailto:Josep.Llovet@mssm.edu)

## ABSTRACT

Primary liver cancer is the second leading cause of cancer-related death worldwide and therefore a major public health challenge. We review hypotheses of the cell of origin of liver tumorigenesis, and clarify the classes of liver cancer, based on molecular features and how these affect patient prognosis. Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare tumors, notably fibrolamellar carcinoma and hepatoblastoma. The molecular and clinical features of HCC vs iCCA are distinct, although they have overlapping risk factors and pathways of oncogenesis. A better understanding of the cell types originating liver cancer can aid in exploring molecular mechanisms of carcinogenesis and therapeutic options. Molecular studies have identified adult hepatocytes as the cell of origin. These cells have been proposed to transform directly into HCC cells (via a sequence of genetic alterations), to de-differentiate into hepatocyte precursor cells (which then become HCC cells that express progenitor cell markers), or to trans-differentiate into biliary-like cells (which give rise to iCCA). Alternatively, progenitor cells also give rise to HCCs and iCCAs with markers of progenitor cells. Advances in genome profiling and next-generation sequencing have led to the classification of HCCs based on molecular features, and assigned them to categories such as proliferation–progenitor, proliferation–transforming growth factor beta, and Wnt–catenin beta 1. iCCAs have been assigned to categories of proliferation and inflammation. Overall, proliferation subclasses are associated with a more aggressive phenotype and poor outcome of patients, although more specific signatures have refined our prognostic abilities. Analyses of genetic alterations have identified those that might be targeted therapeutically, such as fusions in the *FGFR2* gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs) or amplifications at 11q13 and 6p21 (in approximately 30% of HCCs). Further studies of these alterations are needed before these can be used as biomarkers in clinical decision making.

Liver cancer is the second most common cause of cancer-related death worldwide and one of the few neoplasms whose incidence and mortality have been steadily increasing<sup>1, 2</sup>, with the highest increase in mortality in the United States (US) during the last 2 decades (**Figure 1**<sup>3</sup>). Liver cancer comprises a heterogeneous group of malignant tumors with different histologic features and unfavorable prognosis that range from hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) to mixed hepatocellular-cholangiocarcinoma (HCC-CCA), fibrolamellar HCC, and the pediatric neoplasm hepatoblastoma<sup>4, 5</sup>. Among these, HCC and iCCA are the most common primary liver cancers, whereas the other neoplasms, including mixed HCC-CCA tumors<sup>5</sup>, account for less than 1% of cases. The burden of liver cancer is increasing globally—there could be 1 million cases by 2030<sup>6</sup>. It is not clear how direct-acting antiviral (DAA) agents, which can cure hepatitis C virus (HCV) infection, will affect the burden of HCC. It has been estimate that curing more than 90% of patients with HCV infection would eliminate 15% of HCC cases in the US<sup>7</sup>. However, there is debate over the effects of DAA agents on progression of HCC<sup>8-11</sup>.

HCC alone accounts for 90% of all primary liver cancer cases with nearly 800,000 new annual cases<sup>2</sup>. Its highest incidence is in Asia and Sub-Saharan Africa due to the high prevalence of hepatitis B virus (HBV) infection<sup>6</sup>. Unlike other cancers, the main risk factors associated with HCC are well defined and include viral hepatitis (B and/or C), alcohol abuse and non-alcoholic fatty liver disease in patients with metabolic syndrome and diabetes. Other co-factors of HCC development, such as aflatoxin B1 and tobacco, increase the incidence of the disease if other common risk factors are present<sup>12</sup>.

iCCA is the second most common liver cancer, with the highest incidence in Southeast Asia (30–40 cases/10<sup>5</sup> inhabitants) and low incidence in Western countries (fewer than 5 cases/10<sup>5</sup> inhabitants)<sup>13</sup>. Nevertheless, steady increases have been reported<sup>13, 14</sup>. Risk factors for iCCA development include primary sclerosing cholangitis (PSC), biliary duct cysts, hepatolithiasis and parasitic biliary infestation with flukes—an etiology prevalent in Asia and linked to a specific molecular fingerprint<sup>13</sup>. More recently, shared risk factors with HCC have also been identified, such as HBV and HCV—particularly for iCCAs that develop in cirrhotic liver<sup>15</sup>.

HCC and iCCA have been considered to be independent tumors that originate from distinct cell populations. However, more recently, some have been recognized as tumor subtypes of a continuum spectrum of diseases. We review the theories behind the cell(s) of origin of liver

cancer, describe emerging molecular classes, link these classes with their etiology and prognosis, and define pathways for future translation.

## **CELL(S) OF ORIGIN**

Parenchymal (hepatocytes and cholangiocytes) and non-parenchymal cells (fibroblasts, stellate cells, Kupffer cells, and endothelial cells) form the basic hepatic structure (**Figure 2**); the existence of stem cells in adult liver has been heavily debated. Hepatocytes constitute 60%–80% of the total liver mass. Architecturally, these cells are organized in lobules, which can be further divided in functional regions or zones<sup>16</sup>. Liver zonation is particularly relevant for hepatocytes, since it affects their function without altering their phenotype. Hepatocytes are frequently polyploid (4N, 8N, etc.); polyploid cells make up 50% of human liver and 90% of mouse liver<sup>17</sup>.

Liver tumors are heterogeneous in morphology, within the same and between different tumors. Some subtypes of HCCs and iCCAs have stem cell features<sup>18-20</sup>, such as HCCs with CK19-positive cells<sup>21</sup>. The rare, mixed HCC-CCAs have cells with a phenotype that is intermediate between hepatocytes and cholangiocytes<sup>22</sup>. These observations have led to several hypotheses about liver cancer's cell(s) of origin. Hepatic progenitor cells might generate primary liver tumors because, during liver development, hepatocytes and cholangiocytes each arise from a common progenitor (hepatoblasts). Or, HCC and iCCA might be distinct tumors that originate from mature hepatocytes and cholangiocytes, respectively.

We review findings from recent studies indicating that adult hepatocytes are the source of HCCs, because they can directly degenerate into HCC following sequential genomic insults, de-differentiate into precursor cells that ultimately can transform into HCC cells with markers of progenitor cells, and trans-differentiate into biliary-like cells able to transform into iCCA<sup>23-25</sup> (**Figure 3**). In parallel, progenitor cells may also give rise to HCCs and iCCA with progenitor-like features, whereas adult cholangiocytes, which lack the plasticity and transforming capacity of hepatocytes, can only give rise to iCCAs<sup>26</sup>.

### *Progenitor cells and hepatocytes in liver regeneration*

Adult stem cells or somatic stem cells are defined as undifferentiated cells with limitless replicative potential. They can differentiate into all or some specialized cell types, and their primary role is to sustain physiological tissue turnover and to direct tissue repair upon different

types of injury<sup>27</sup>. Stem cell compartments have been successfully identified in several adult tissues with fast turnover, including the gastrointestinal tract, skin, and bone marrow. Because of their self-renewal potential and long lifespan, these cells are thought to be more prone to malignant transformation<sup>28, 29</sup> and have been identified as the cell of origin of cancer in several organs, for example skin and intestine<sup>30-32</sup>. Unlike these organs, however, cells of the adult liver have relatively slow turnover (a period of several months), with an average hepatocyte life span ranging from 200 to 300 days<sup>33, 34</sup>. In this context, the contribution of stem cells to liver turnover is unclear (reviewed in ref. <sup>35</sup>).

Hepatocytes are quiescent in normal liver, but their turnover in the liver dramatically accelerates upon hepatic injury or after a significant reduction of liver mass such as following partial hepatectomy. Under these conditions, adult hepatocytes have enormous proliferative potential (capacity to replicate more than 50 times), a feature that has enabled human liver organ donor transplantation as a standard procedure to treat end-stage liver disease<sup>33-35</sup>. There is evidence that regeneration after partial hepatectomy relies predominantly on the replication of hepatocytes, rather than stem cells. However, when the replicative capacity of hepatocytes is severely impaired, such as in patients with acute liver failure or chronic hepatitis, epithelial cells with intermediate hepatocyte–cholangiocyte phenotypes emerge and expand<sup>36-38</sup>. These cells, also known as oval cells, are thought to localize to the peri-portal area in the canals of Hering and are considered to be bi-potential progenitors<sup>35, 39</sup> (**Figure 2**). The capacity of these cells to repopulate the damaged liver has been demonstrated in mice with massive liver damage, restoring more than 80% of hepatocytes<sup>40</sup>. Other studies from liver injury models have supported the liver stem cell hypothesis, showing proliferation of duct-like cells, frequently termed the ductular reaction, in the portal zone of the hepatic lobule<sup>41-43</sup>. However, this feature is controversial<sup>44, 45</sup>.

Other cells have been implicated in regeneration, repair, and eventually carcinogenesis. HCV-related chronic injury can induce ductular metaplasia and proliferation, with mature hepatocytes trans-differentiating to bi-potential oval cells via epigenetic re-programing<sup>25</sup>. These cells are different from the classical oval cells of the canals of Hering, and may have a more relevant role in hepatocarcinogenesis. However, other sources of precursors have been identified. These include specialized peri-central liver cells, capable of self-renewal in the uninjured liver under the influence of endothelial Wnt signaling<sup>46</sup>. These pericentral cells express the early liver progenitor marker TBX3<sup>47</sup> and are diploid. Hybrid periportal cells express hepatocyte markers,



along with low levels of SOX9 and several bile duct genes, are able to repopulate the healthy and diseased liver mass<sup>48</sup>. It is not clear whether these cell populations are bona fide stem or progenitor cells, or distinct hepatocyte subpopulations, and whether they contribute to tumorigenesis<sup>49</sup>.

#### *Progenitor cells as precursors*

Extensive experimental studies support the hypothesis that progenitor cells might originate liver cancer<sup>50-52</sup> (**Table 1**). For example, mice with genetic alterations that affect the Hippo pathway within the liver expand progenitor-like cells and subsequently develop HCC, iCCA, and mixed HCC-CCA<sup>53-55</sup>. Similarly, liver-specific deletion of the neurofibromatosis type 2 (*NF2*) tumor suppressor gene in developing or adult mice leads to expansion of progenitor cells without affecting differentiated hepatocytes; these mice develop HCC and iCCA<sup>56</sup>. Furthermore, any mouse hepatic cell, including hepatic progenitors, hepatoblasts, and hepatocytes, that express activated oncogenes (such as H-RAS or SV40LT) can undergo transformation to develop into iCCAs or HCCs<sup>57</sup> (**Table 1**). There could also be subpopulations of stem or progenitor cells in peribiliary glands, located throughout the biliary tree,<sup>58</sup> that give rise to iCCAs<sup>59</sup> or fibrolamellar HCC<sup>60</sup>. Proteins involved in stem cell renewal and cell fate decisions include MET<sup>50</sup>, which primarily induces hepatocyte differentiation, and EGFR and Notch, which promote cholangiocyte specification<sup>50, 51</sup>. Activation of Notch in mice leads to development of HCC<sup>61</sup> and iCCA<sup>62</sup>. In addition, mutations in genes encoding isocitrate dehydrogenases, frequently detected in iCCAs<sup>14</sup> but rarely in HCCs, inhibit hepatocyte differentiation and promote oval cell proliferation and biliary transformation following liver injury, in cooperation with *KRAS* mutations<sup>63</sup> (**Table 1**). Similarly, *KRAS* mutations and homozygous *PTEN* deletion in embryonic bi-potential progenitor cells cooperate to induce onset of iCCA<sup>64</sup>. Overall, these experimental studies implicate progenitor cells in the development of the two most common primary liver cancers.

#### *Adult hepatocytes as cell of origin*

There is significant experimental evidence implicating adult hepatocytes as the cell of origin in liver cancer<sup>48, 65-69</sup>. Studies using fate-tracing systems have observed that HCC does not originate from progenitor cells, but rather from hepatocytes in both hepatotoxin-induced<sup>66, 67</sup> and carcinogen-free (*Mdr2* knock-out) models<sup>65, 67</sup> (**Table 1**). In particular, these data indicate that Foxl1+ cells, which express the progenitor markers EPCAM, SOX9, PROM1, do not contribute to HCC tumorigenesis<sup>66</sup>, in agreement with other studies showing that biliary cells do not give

rise to HCC<sup>65</sup>. In addition, a recent study has demonstrated that hepatocyte-specific p62 expression promotes c-MYC induction, mTORC1 activation and HCC initiation<sup>70</sup>.

Adult hepatocytes, however, have additional properties consistent with a cell that originates cancer. These include their remarkable plasticity, which entails their capacity to de-differentiate into a progenitor state and then can restore the hepatocyte pool<sup>25</sup>. Mature hepatocytes can de-differentiate following loss of the tumor suppressor *TP53*, which yields nestin-positive progenitor-like cells that can expand and generate primary liver cancers after acquiring lineage-specific oncogenic lesions, such as mutations in WNT (in HCC) or Notch (in iCCA)<sup>52</sup> (**Table 1**). In addition, adult hepatocytes can also trans-differentiate into biliary-like cells (**Figure 3**)<sup>24</sup> that can degenerate into iCCA. Upon injury, Notch activation leads to reprogramming of mature hepatocytes into cells that closely resemble biliary epithelial cells,<sup>71</sup> to induce iCCA. Notch can do this on its own<sup>72</sup> or in cooperation with AKT<sup>73</sup> (**Table 1**).

There is evidence that different cell types can serve as the cell of origin for primary liver cancers (**Figure 3, Table 1**). Two complementary features of HCC and ICCAs could account for their phenotypic complexity, their molecular features (pathways of activation, mutations, etc.), and the types of cells that become transformed. For example, development of HCC could involve specific molecular alterations in adult hepatocytes (**Figure 3**), whereas iCCA could originate from cholangiocytes, probably as a result of chronic biliary damage due to liver flukes, PSC, or other insults.

However, adult hepatocytes have also been implicated in the formation of other tumor types. First, tumors with progenitor cell phenotype could derive from progenitor-like cells, either because they are bona fide progenitor cells or following de-differentiation of adult hepatocytes. Transformation of progenitor cells could occur at any stage of hepatic development—from progenitor to adult liver cells—giving rise to tumors of different morphologies, ranging from HCC and iCCA with stem-cell phenotypes to mixed HCC-CCAs (**Figure 3**). Clinical and pathology analyses of mixed HCC-CCAs have indicated an origin from the progenitor cell compartment<sup>5, 14, 74</sup>. Finally, mature hepatocytes can trans-differentiate, generally as a result of viral infection, to biliary-like cells that give rise to iCCA.

Regardless of their cell of origin (mature hepatocytes vs progenitor cells), liver cancers with stem cell features have a more aggressive clinical behavior and worse prognosis than those without stem cell features<sup>19, 21</sup>. However, these are difficult to study due to discrepancies

between mice and humans. Studies are needed to determine under what circumstances adult hepatic cells, rather than progenitor cells, give rise to liver tumors and vice versa, and to fill the gap between findings from animal models (cell fate tracing studies) and studies patients with severe liver injury. It will also be important to determine the dominant reprogramming events involved in tumorigenesis in different species. Studies should explore which cells are most affected by oncogene mutations associated with HCC, such as those in the *TERT* promoter or *CTNNB1*.

### **Immune Response**

Regardless of the cell type that becomes transformed to initiate tumorigenesis, the developing tumor also requires a specific microenvironment. This is particularly relevant to liver tumors, 90% of which develop under conditions of chronic inflammation<sup>2</sup>. Factors that contribute to tumor formation include changes in the liver's extracellular matrix, signaling between parenchymal and non-parenchymal cells, and immune dysfunction<sup>75</sup>. An altered immune response is an important factor in carcinogenesis.<sup>76</sup> Cancer cells produce growth and angiogenic factors that promote tumor growth, invasion, and metastasis. iCCAs develop under conditions of chronic inflammation, due to viral infections (in about 20% of cases), chronic fluke infestation, PSC, and hepatolithiasis<sup>13</sup>.

Chronic inflammation contributes to liver carcinogenesis through a cycle of cell death and regeneration, leading to production of cell survival and proliferation signals that promote formation of regenerative nodules, dysplasia, and cancer<sup>75</sup>. In this context, the phenotype of liver tumors could depend on interactions between oncogenes and the immune microenvironment. In a recent animal study, different types of liver tumors, such as HCCs, iCCAs, and mixed HCC-iCCA arise via activation of distinct oncogenes, such as *AKT1* and *CTNNB1*, in combination with inflammatory microenvironment conditions, such as carbon tetrachloride or 3,5-diethoxycarbonyl-1,4-dihydrocollidine<sup>77</sup>. Tumors that develop via activation of the same oncogenes can still have different transcriptomes, depending on level of inflammation and features of the microenvironment.

Several mechanisms have linked the immune system with liver cancer development. First, secretion of cytokines by immune cells, such as tumor necrosis factor and IL6, can activate inflammatory signaling pathways in hepatocytes, via JAK–STAT, nuclear factor (NF)-kB, etc., to promote cell proliferation and survival<sup>75</sup>. A model of HCC tumorigenesis has been proposed in

which leukocytes that infiltrate the liver organize into ectopic lymphoid-like structures, providing microniches that contain malignant hepatocytic progenitor cells<sup>78</sup>. The role of the adaptive immune system is becoming apparent from studies of animal models of liver cancer development with non-alcoholic steatohepatitis. Factors that activate inflammation, such as NF- $\kappa$ B and insulin receptor, contribute to carcinogenesis in patients with non-alcoholic fatty liver disease<sup>79</sup>. CD8+ and CD4+ T cells and natural killer cells<sup>80,81</sup> also promote oncogenesis.

The interaction between inflammation and iCCA development has been demonstrated in mice in which biliary epithelial cells that express transgenic *AKT* and *YAP* develop only iCCA upon promotion of IL33-mediated biliary tract inflammation<sup>82</sup>. Other inflammatory mediators that contribute to oncogenesis include IL6 and iNOS<sup>83</sup>. IL6 is highly expressed in human CCAs and promotes cell survival in a STAT3-dependent manner<sup>84</sup>. Interestingly, a gene expression signature associated with IL6–STAT3 signaling has been observed in a subset of human iCCAs<sup>85</sup>.

Normally, nascent transformed cells are eliminated by both the innate and adaptive immune systems in a process called immune surveillance. Cancer cells express antigens that induce adaptive responses mediated by T cells<sup>86</sup>. In the chronically inflamed liver, immune surveillance prevents proliferation and expansion of cancer cells. Some, but not all, recent reports have warned about an unexpectedly higher incidence of HCC occurrence and recurrence in patients treated with DAAs for HCV infection<sup>8-11</sup>. If confirmed, the potential role of immune system should be explored, because rapid clearance of HCV in patients with chronic infection for years might affect immune surveillance.

### *Immune therapies*

The immune microenvironment of HCC is characterized by the co-existence of immune responses leading to both immunogenicity and tolerance<sup>87</sup>. HCCs promote immunotolerance through the release of cytokines such as interleukin 10 (IL10) and transforming growth factor beta (TGFB). The tumors and tumor-infiltrating immune cells also express immune regulators such as programmed cell death protein 1 (PD1), its ligand PDL1, and cytotoxic T-lymphocyte protein 4 (CTLA4), which suppress the anti-tumor immune response, allowing tumor growth and progression<sup>87, 88</sup>. Tumors with immune infiltrates have been associated with longer survival

times and reduced relapse after resection and transplantation<sup>2, 88</sup>. In addition, some HCC cases of spontaneous regression have been linked to immune-mediated mechanisms<sup>2</sup>. These observations establish the rationale for immunotherapy of HCC. Promising responses have been reported with nivolumab, a monoclonal antibody directed against PD1, in a phase 2 trial<sup>89</sup>. It appears that a T-cell response, features of inflammatory cells (PD1, PDL1 expression), number of mutations in tumor cells, and gene expression profiles might predict patient responses<sup>90-93</sup>. Using source separation techniques to dissect gene expression patterns of tumor cells from those of tumor-infiltrating immune cells, an immune-specific subclass has been identified in 25% of HCC patients<sup>94</sup>. This subgroup is characterized by activation of immune cells, expression of PD1 and PDL1, and enrichment in signatures of response to immunotherapies. Furthermore, 2 robust microenvironment-based types have been identified, with either active or exhausted immune responses; these findings could be used to improve design of clinical trials of immunotherapies<sup>94</sup>. Similarly, a subtype of iCCA characterized by high mutation load and increased expression of immune checkpoint genes has been identified that may predict response to immunotherapies<sup>95</sup>.

### **Classification Based on Molecular Features**

Characterization of molecular subtypes and/or oncogene-addiction loops has generated treatment algorithms for several types of cancer, including breast cancer; these have improved patient outcomes. High-throughput technologies, including single-nucleotide polymorphism arrays, combined with transcriptomic and exome sequencing analyses, have identified molecular subtypes of liver cancer, with distinct oncogene signaling pathways and recurrent mutations<sup>96</sup>. Even though molecular classifications have not affected decision making for patients with liver cancer, correlations between these subclasses and clinical and pathology characteristics (such as risk factors, outcome, etc.) have been proposed.

### *Reaching a consensus*

The development of a molecular classification of HCC has paralleled the progress in genomic profiling technologies, and is extensively reviewed elsewhere<sup>97</sup>. Initial studies relied on differences in gene expression patterns determined by microarrays, whereas more recent, sequencing-based studies used mutation signatures to classify HCCs<sup>3</sup>. Unsupervised clustering of gene expression patterns accurately identified 2 major subgroups (reviewed in<sup>2, 97</sup>). These 2 classes, broadly termed proliferation and non-proliferation, correlate with clinical and pathology features, etiology, and patient outcomes<sup>97</sup>. Tumors of the proliferation class are highly

heterogeneous with significant enrichment in signaling pathways related to proliferation, such as insulin like growth factor 1 (IGF1)<sup>98</sup> and mechanistic target of rapamycin (MTOR) or stem cell features, such as Notch<sup>61</sup>. This class also contains most gene expression patterns associated with tumor recurrence<sup>99</sup> and shorter survival time<sup>100</sup> (**Figure 4**). Epigenetic features, such as expression patterns of micro RNAs<sup>101</sup> and DNA methylation patterns,<sup>102</sup> also associate with these subclasses. Chromosomal aberrations are also frequent in HCCs—mostly in chromosomes 1 and 8—which correlate with transcriptome-based subclasses. High-level amplifications have been reported at Chr. 11q13 (at *CCND1* and *FGF19*) and 6p21 (at *VEGFA*); gains in 11q13 are enriched in tumors from the proliferation subclass (**Figure 4**). Tumors in the non-proliferation subclass tend to retain hepatocyte-like features; a subset has activation of the canonical WNT signaling pathway, mostly via mutations in *CTNNB1*<sup>97</sup>. This class contains many less-aggressive, well-differentiated tumors with low levels of alpha fetoprotein, compared to the proliferation class. In parallel, molecular analyses of the adjacent non-tumor tissues have provided valuable insights into mechanisms that promote hepatocarcinogenesis, including aberrant EGF signaling and activation of inflammation pathways (involving NF-κB and IL6)<sup>103, 104</sup>.

Next-generation sequencing (NGS) has provided a more detailed picture of molecular alterations in HCCs<sup>105</sup>. This technique can be used to define mutation signatures—recurrent patterns of nucleotide substitutions across different samples. These data provide for an additional layer of stratification beyond transcriptome-based classes. Interestingly, mutation signatures can reflect the exposure history of a tumor. In HCC, specific mutation signatures are associated with environmental exposures such as smoking, alcohol, aflatoxin B1 or aristolochic acid<sup>96</sup> (**Figure 4**). Data from exome sequencing of large patient cohorts have confirmed the most prevalent mutations in HCC pathogenesis<sup>106, 107</sup> (such as the *TERT* promoter, *CTNNB1*, *TP53*, *AXIN1*, *ARID1A*), but also uncovered novel low-frequency events<sup>106, 107</sup> and implicated mutations in non-coding DNAs<sup>108</sup>. In addition, NGS has also provided a map of viral integrations in HCC, mostly related to HBV<sup>109</sup> and more recently for the adeno-associated virus type 2 (AAV2)<sup>110</sup>. Recurrent clonal HBV integrations affect *TERT*, *MLL4* and *CCNE1*, some of which may impact patient survival<sup>109</sup>. AAV2-mediated insertional mutagenesis has been reported in 5% of HCC, mostly in non-cirrhotic patients without a clear etiological factor, predominantly affecting *TERT*, *KMTB2*, *CCNA2* and *CCNE1*<sup>110</sup>.

### *Obstacles to clinical implementation*

Ultimately, molecular classification of both the tumor and its microenvironment will translate into more effective clinical decision-making and treatment selection. This means optimizing clinical staging systems, both in their ability to predict prognosis and in their capacity to stratify patients based on response to therapies. Despite substantial progress, clinicians cannot yet use molecular information to guide therapy, primarily because there are not yet biomarkers that predict the response to a given therapy, unlike other malignancies. For instance, lung cancer patients with ALK rearrangements have a significantly better response to ALK inhibition with crizotinib than those without ALK rearrangements<sup>111</sup>.

There are several reasons that molecular information on tumors is not incorporated into clinical practice. Unlike other solid tumors, the most frequent mutations in HCC are un-targetable, including those in the *TERT* promoter (60%–70%), *TP53* (25%–50%) and *CTNNB1* (25%–30%). Furthermore, the few potentially actionable events uncovered have not yet been evaluated in clinical trials that include biomarkers. Only recently have some potential biomarkers been tested in early clinical trials, such as FGFR4 inhibitors in patients with high level amplifications of Chr11q13, locus of FGF19<sup>112</sup>. Finally, a therapeutic response to blocking an oncogene in a few patients will be lost among many patients who lack a responsive phenotype if the trial has not been enriched to include those patients whose tumors harbor targetable defects. A recent report suggests that *TSC2* loss predicts response to the MTOR inhibitor everolimus in different experimental models of HCC<sup>113</sup>, yet there is no clear biomarker of treatment response in the phase 3 clinical trial<sup>114</sup>. Indeed, the two systemic therapies that increase survival in HCC patients in first (i.e., sorafenib<sup>115</sup>) and second line (i.e., regorafenib<sup>116</sup>) have been tested in ‘all-comers’, with no patient enrichment strategy.

Options to improve the current trial strategy could include conducting clinical trials with enriched populations, based on biomarkers that predict response (FGF19<sup>117</sup>, MET). Or they could investigate non-mutated de-regulated pathways as targets, such as IGF2<sup>98</sup>, or NOTCH<sup>61</sup> signaling. It might also be possible to use alternative anti-tumor approaches, such as immune checkpoint inhibitors, or strategies to antagonize the most prevalent genetic defects found in HCCs, such as mutations in *TERT*, *TP53* and *CTNNB1*.

## Molecular Subclasses of iCCA

There is no effective treatment for iCCA. Reasons include our poor understanding of its pathogenesis and the lack of studies conducted specifically in patients with iCCA, apart from patients with all biliary tract cancers<sup>13, 14</sup>; this is important because iCCAs are characterized by a distinct set of mutations<sup>14</sup>. iCCAs were only recently recognized as a distinct entity with both its own unique staging system (see the 7th edition of the American Joint Committee on Cancer Staging Manual<sup>118</sup>) and ad hoc practice guidelines [see guidelines of the International Liver Cancer Association (ILCA)<sup>13</sup>]. The classification of iCCA's distinct phenotype has led to the first studies that characterize its genomic landscape in order to generate an initial molecular classification. Other CCA, such as perihilar (pCCA) and distal (dCCA) are different molecular entities<sup>14</sup>.

Two main molecular subtypes of iCCA, proliferation and inflammation, have been proposed based on an integrative analysis of whole-genome expression patterns, chromosomal aberrations, mutation, and alterations in signaling pathways in a large cohort from USA and Europe<sup>85</sup>. The inflammation subclass was characterized by activation of inflammatory pathways, overexpression of cytokines, and STAT3 activation, whereas the proliferation subclass was characterized based on activation of oncogene signaling pathways (KRAS, EGFR, and Notch) and HCC gene expression signatures associated with short survival times and earlier recurrence<sup>85</sup>. While neither of the two subclasses displayed specific broad chromosomal gains and losses, the proliferation subclass is enriched in focal aberrations including DNA amplifications at 11q13.2 (locus of CCND1 and FGF19), and deletions at 14q22 (locus of SAV1). The proliferation class also includes a subtype with stem cell-like features<sup>119</sup>, chromosomal instability<sup>85</sup> and mutations in isocitrate dehydrogenase genes<sup>63</sup> (**Figure 5**). Clinical characteristics such as moderate/poor differentiation, intra-neural invasion and poor outcome are significantly more frequent in the proliferation class. Interestingly, there is a genomic resemblance observed between the proliferation subclass of iCCA and HCC subtypes with poor prognosis (i.e. cluster A<sup>19</sup>, G3<sup>120</sup>) and stem cell features (S2)<sup>121, 122</sup> (**Figure 5**). This evidence further supports the presence of a common cell of origin in liver cancers.

An independent whole-transcriptomic analysis of a large cohort including iCCA and extrahepatic cholangiocarcinomas also confirmed the existence of the two prognostic CCA molecular subtypes<sup>123</sup>. In this study, two main classes were reported: a poor prognosis group characterized by enrichment of *RAS* mutations, *MET* and *EGFR* overexpression, and a good



prognosis subgroup characterized by signatures of immune response<sup>123</sup>. Genomic overlap between the poor prognosis group<sup>123</sup> and the proliferation subclass was observed<sup>85</sup>.

Similar to HCC, NGS studies have generated insights into the molecular subtypes of iCCA<sup>95, 124-131</sup>. The most common genetic aberrations include *FGFR2* gene fusions (~25%) and mutations in *KRAS* (20%), *IDH1/2* (~20%) and chromatin remodeling genes [*ARID1A*, *BAP1*, *PBRM1*, ~30%,] (reviewed elsewhere<sup>14</sup>). Besides *IDH1* and *IDH2*<sup>63</sup>, *KRAS*,<sup>85, 123</sup> and *EGFR*<sup>85</sup> mutations, which are enriched in the proliferation subclass, no significant distribution of other molecular aberrations has been reported in any of the iCCA molecular subtypes.

The incidence of iCCA varies significantly among geographic regions. Incidence is highest in Asian countries, where infections with liver flukes such as *Opisthorchis viverrini* and *Clonorchis sinensis* are the major risk factor<sup>13</sup>. In non-endemic regions, other factors, including hepatolithiasis and PSC, likely contribute to risk. Associations between different risk factors and mutations detected in iCCAs were explored in 209 CCAs from Asia and Europe. Mutations in *BAP1* and *IDH1/2* were found in a higher proportion of non-*O viverrini*-related iCCAs (22% vs 3.2%), whereas mutations in *TP53* were found in a higher proportion of tumors from patients with *O viverrini* infection (45.2% vs 7.4%)<sup>124</sup>. Although there have been other studies of large cohorts of patients, it has been difficult to draw conclusions from these due to the different types of neoplasms included (iCCAs, extrahepatic cholangiocarcinomas, and gallbladder tumors)<sup>85, 123</sup>.

Importantly, multiple *FGFR2* gene fusions have been discovered in approximately 25% of iCCAs<sup>126, 127, 132-135</sup> (reviewed in ref. <sup>14</sup>); these are used to define tumor subtypes. Tumors with *FGFR2* fusions and *KRAS* mutations<sup>126</sup> or *BAP1* mutations<sup>95</sup> have been reported. No significant differences in patient age or outcome, or tumor differentiation or stage, were found in comparing patients with or without the *FGFR2* fusion. One study reported a higher frequency of HCV infection in patients with *FGFR2* fusions<sup>132</sup>, although this finding has not been confirmed<sup>95, 126, 134</sup>. Early-phase clinical trials testing selective FGFR inhibitors in advanced iCCA patients carrying alterations in *FGFR2* are underway (NCT02150967 and NCT01752920)<sup>136, 137</sup>. These studies reported an objective response rate of approximately 15% (a signal of efficacy) and manageable safety profile<sup>136</sup>. The discovery that *FGFR2* fusions can promote development of iCCAs has been quickly translated to clinical trials. Fusions of the *FGFR2* gene might be used as biomarker to select patients for treatment with these agents.

## Molecular Features of Uncommon Tumors

Fibrolamellar HCC (FLC) is a rare primary liver cancer with few treatment options that typically affects children and young adults without background liver disease<sup>60</sup>. FLC is now considered a unique molecular entity within primary liver malignancies<sup>138</sup>. FLC is caused by an approximate 400 kb deletion in chromosome 19 that incorporates the first exon of *DNAJB1* into all but the first exon of *PRKACA*<sup>139</sup>. This fusion is detected in 70%<sup>138</sup> to 100% of FLCs<sup>139</sup>. In addition, exome sequencing and RNA sequencing studies found de-regulation of additional actionable candidates such as *ERBB2* and *AURKA*<sup>140</sup>. Unlike HCC or iCCA, there are no prevalent mutations in more than 10% of patients. Unsupervised clustering of gene expression data identified FLC molecular subclasses in a cohort of 58 FLCs, 2 of them associated with proliferative and inflammatory molecular traits. The same study provided a prognostic 8-gene expression signature<sup>138</sup>. FLC has less chromosomal aberrations compared to HCC or iCCA without recurrent high-level amplifications or deletions.

Hepatoblastoma is the most frequent primary liver tumor in children younger than 5 years old. Like FLC, background liver disease is rare in these patients. WNT signaling plays a major role, with *CTNNB1* mutations (70%) as the most frequently reported molecular event. Integrative analysis of gene expression and chromosomal aberrations in 24 hepatoblastoma samples distinguished 2 classes, with different DNA gains, histological phenotype and clinical outcome<sup>141</sup>. The recent use of patients-derived xenografts (PDX) in hepatoblastoma enabled the identification of novel therapeutic targets such as *NRAS* mutations<sup>142, 143</sup>.

Mixed HCC-iCCA is a rare neoplasm accounting for less than 1% of all primary liver cancers<sup>5</sup>. Diagnosis is mainly based on histological examination and requires features of HCC and iCCA. According to the 2010 World Health Organization classification, there is a classical type, characterized by areas of typical HCC and iCCA with a transition area, and a stem cell-feature type<sup>144</sup>. The stem cell-feature type can be further divided into typical, intermediate, and cholangiolocellular carcinoma (CLC) subtypes. Gene expression profiling of small series of HCC-CCA samples indicated that this tumor type might share common characteristics with poorly differentiated HCC and iCCA with stem cell traits<sup>119, 122, 145</sup>. A comprehensive integrative genomic analysis of 18 mixed HCC-CCA subtypes defined 3 molecular types (CLC, stem cell, and classical subtype)<sup>146</sup>. In particular, the CLC subtype, despite being grouped, based on histology, within the stem cell-feature subtype, has a unique molecular profile, with biliary traits,

low levels of chromosome instability, and activation of TGFB and inflammation-related signaling pathways<sup>146</sup>.

### **Challenges in tumor heterogeneity**

Liver tumors have a high degree of molecular heterogeneity, not only among patients with the same types of tumors, but also within regions within the same tumor or tissue<sup>147</sup>. Expert recommendations and consensus definitions have been established to better address the extent and role of cancer heterogeneity in oncology research<sup>148</sup>.

From a clinical perspective, molecular heterogeneity should be considered within the concepts of trunk and branch, and driver and passenger mutations. Trunk mutations (mutations that occur early in tumorigenesis) can be found in every cancer cell of a tumor<sup>148</sup>. Branch mutations are found in only a subgroup of tumor cells; these are acquired at later stages of tumor development, frequently following treatment, and are associated with resistance. Studies of other malignancies have indicated that trunk mutations promote tumor progression, and are therefore the best targets for therapies. Trunk mutations identified in single-biopsy should be the first targets of molecular therapies<sup>2</sup>. Finally, passenger mutations account for the most common type of mutations, but their relevance to tumor development is marginal. However, they are often used to define a tumors' clonal features and anti-tumor response.

### **Prognostic Markers**

Molecular biomarkers have many applications in cancer. They can improve clinical decision making by helping to predict a patient's outcome, select the patients most likely to respond to a specific treatment, and avoid treatments not likely to be effective. Unlike other cancers such as breast<sup>149</sup> and colorectal<sup>150</sup> cancers, HCC has no molecular markers that have been incorporated into clinical management.

As a general rule, clinical practice guidelines include recommendations based on a specified set of metrics, which rate the level of evidence and the strength of recommendations for each statement; the higher the evidence, the stronger the recommendation. For example, sorafenib is recommended for treatment of patients with advanced-stage HCC; a strong recommendation was derived from a prospective, double-blind, randomized, placebo-controlled trial (the highest level of evidence)<sup>151</sup>. These metrics are less clear when evaluating biomarkers for HCC. Initial recommendations for biomarkers were developed mostly to address technical aspects of the

assay such as the Tumor Marker Utility Grading System<sup>152</sup>. This was later improved upon by the REMARK guidelines for reporting prognostic biomarker in oncology<sup>153</sup>, which also has addressed issues related to clinical utility. The PROGRESS initiative was the most recent attempt to provide a methodological framework for biomarker research<sup>154</sup>.

The highest level of evidence in biomarker research (Level A) comes from randomized trials<sup>155</sup>. A large prospective study of 10,253 women demonstrated that a 21-gene expression signature could identify patients with early-stage breast cancer at high risk for recurrence<sup>156</sup>. Level B evidence is provided by companion studies of biomarkers in randomized clinical trials, such as those reported for HCC in the Sorafenib HCC assessment randomized protocol<sup>157</sup> and everolimus for liver cancer evaluation<sup>114</sup> trials. Neither of these studies identified markers associated with response to either sorafenib or everolimus, but they confirmed the prognostic role of levels of angiopoietin 2 and vascular endothelial growth factor in plasma of patients with advanced-stage HCC<sup>157</sup>. Level C evidence has been provided most frequently for markers of HCC, from studies of archived samples, with extensive validation (reviewed elsewhere)<sup>97</sup>. Most level C studies have evaluated prognostic markers, identifying patients with the proliferation subclass of tumor, either S1 (WNT and TGFB expression), or the S2 (progenitor cell) subtype<sup>97</sup>, with or without amplification of *FGF19*<sup>106</sup>. The S2 subtype expresses many markers of progenitor cell cells and high levels of alpha fetoprotein. Tumors in the S1–S2 subgroups are poorly differentiated and patients have worse outcomes than patients with other HCC subtypes<sup>97</sup>. Level D evidence comes from studies of convenience, in which specimens were collected for unknown reasons and happen to be available for assay.

Gene signatures associated with risk of HCC development may have a more direct application (**Table 2**)<sup>100, 102, 158-161</sup>. For instance, a 186-gene signature in liver tissues was able to predict occurrence of HCC<sup>158</sup> in patients with hepatitis C-related early-stage cirrhosis, and might be used to select patients for trials of chemopreventive agents (**Figure 4, Table 2**). However, chemoprevention studies are a challenge, because it takes a long time to collect data on a low number of events. Studies that included populations of patients at high-risk for HCC may shorten trial time and identify effective agents more quickly. For predictive biomarkers in advanced HCC, ongoing clinical trials include populations selected based on high expression of MET in tumor cells (trial of tivantinib, NCT01755767) or high serum level of alpha fetoprotein (trial of ramucirumab, NCT02435433), both as second-line therapies.

## Molecular markers of iCCA

Even fewer biomarkers of iCCA have been developed than for HCC; there is only level C data for the efficacy of a biomarker for this tumor type. iCCA is one of the few solid tumors for which no systemic molecular therapy has been approved by the Food and Drug Administration<sup>13</sup>. Surgery is the only potentially curative option, although chemotherapy with gemcitabine plus cisplatin is the standard for patients with advanced-stage iCCA<sup>162</sup>. According to the ILCA practice guidelines, no studies have provided level A or B evidence for a marker of this tumor—some data from low-quality studies have led to weak recommendations<sup>13</sup>. These studies have been retrospective in design, without extensive validation in independent cohorts. Some gene expression and microRNA patterns have been associated with features of iCCA<sup>85, 119, 123</sup>, as well as mutations in *KRAS* and *IDH1* or *IDH2* and focal deletions at 14q22.1<sup>85, 128, 129</sup> (**Table 2**). Gene expression patterns have been reported to identify an iCCA proliferation subclass of tumor<sup>85</sup>, patients with a poor prognosis,<sup>85, 123</sup> and tumors with a stem cell–like subtype<sup>119</sup>, who have aggressive disease and worse outcome.

Features of cancer cells in a tumor determine not only the tumor's growth and progression, but also affect the tumor microenvironment (non-cancer cells and supporting stroma)<sup>76</sup>. Some studies associated features of the iCCA microenvironment with patient outcome<sup>123, 163-165</sup>. Two studies identified a stromal signature associated with shorter survival time by combining laser capture microdissection with gene expression profile analysis<sup>123, 165</sup>. Although many studies have validated gene expression signatures associated with patient outcomes, the clinical significance of microRNA signatures is not yet clear, due to the limited number of large comprehensive profiling studies<sup>119, 166-168</sup>.

Mutations in oncogenes such as *KRAS* and *BRAF* can be used to determine prognosis for patients with pancreatic or colorectal cancers<sup>169-171</sup>. However, there is controversy over whether these mutations can predict outcomes of patients with iCCA. Some studies have reported significant associations between mutations in *KRAS*<sup>128, 129, 131</sup> or chromatin-remodeling genes (*BAP1*, *PBMR1*, and *ARID1A*)<sup>125, 172</sup> and either shorter disease-free survival or shorter overall survival, respectively. It is not clear whether mutations in *IDH1* or *IDH2* associate with overall survival<sup>125, 129, 173</sup>.

Most biomarker assays use cells or tissue collected by invasive biopsy procedures or from resection specimens, but these specimens are rarely collected from unresectable or metastatic

iCCAs—the tumors of most patients in clinical trials for iCCA. Strategies should be developed to assess circulating markers (called a liquid biopsy), from tumor cells and cell-free nucleic acids in blood<sup>174</sup>. Detection of molecular signatures or aberrations in the blood could significantly facilitate implementation of prognostic markers. Liquid biopsies might also be used to monitor response to treatment, especially in clinical trials of selective inhibitors of IDH1 and IDH2 (NCT02073994, NCT02273739) and FGFR2 (NCT02150967)<sup>14, 136</sup>.

### **Future Directions**

In the last decade, there have been tremendous advances in our understanding of the cellular and molecular complexity of liver cancers. Sophisticated functional studies and NGS-based research studies have provided information about the cells that form liver tumors and the proteins and pathways involved in hepatocarcinogenesis. These studies support a model of multiple cells of tumor origin. Most of the studies, using *in vivo* lineage tracing models, revealed an unexpected plasticity of mature hepatocytes<sup>24, 25, 44, 52, 72</sup> that could be involved in their transformation into cancer cells. Hepatic progenitor cells might also become transformed to give rise to different subtypes of HCC, iCCA, and mixed HCC-iCCA with progenitor markers.

Studies of humanized mice to mimic the onset of liver cancers in multiple settings may help address existing challenges. In addition, cell- and lineage-tracing models should improve so that they recapitulate the severity of liver injury observed in humans, and must clarify if hepatic progenitor cells can replenish the liver mass after marked liver injury, as demonstrated in zebrafish models<sup>175</sup>. Finally, linking the main genomic hits at pre-neoplastic and early stages of human cancer development with the cell of origin is also an area where further studies are required.

Identifying the cells that give rise to liver tumors and elucidating the different classes of tumors, based on their molecular features, could lead to new approaches to treatment and prognosis. Our knowledge of the molecular mechanisms of HCC and iCCA pathogenesis has not yet been translated into clinical tools, because few studies have linked specific molecular classes of tumors or aberrations to responses to therapy. It is important to incorporate biomarker studies into trials, as in the trials of patients with iCCAs with FGFR2 aberrations<sup>136</sup>. The successes of immune therapies in different solid tumors, including HCC,<sup>176</sup> indicate the need to focus greater attention on the hepatic tumor microenvironment and interactions between the tumor and the immune response; we also need to identify markers of response to these therapies. Learning

more about the effects of tumor heterogeneity, and the use of liquid biopsies to determine the molecular and genetic features of patients' tumors, could overcome barriers to personalized treatment of liver cancer<sup>174</sup>.

## FIGURE LEGENDS

**Figure 1: Mortality trends of patients with different malignancies in the USA from 1990 through 2009** (reprinted from ref <sup>3</sup>). Changes in cancer mortality, among tumor types, in the US. Mortality from liver and bile duct cancers is increasing more rapidly than any other cancer, in men and women. Data obtained from the 2013 American Association for Cancer Research Cancer Progress Report.

**Figure 2: Structure of the liver lobule and location of candidate cell of origin of liver cancer.** Intrahepatic organization of the liver lobule and the localization of hepatic cells that form liver tumors. Different types of cancer (i.e. HCC, iCCA, mixed HCC-iCCA) can originate in the liver depending on the transformation event and the cell type undergoing neoplastic transformation. Hepatic stem or progenitor cells are believed to reside within the most terminal branches of the biliary tree (referred to as Canals of Hering). Upon injury hepatocytes can undergo reversible ductal metaplasia and de-differentiate into hepatocyte-derived progenitor-like cells.

**Figure 3: Multiple cells of origin of primary liver cancers.** HCC and iCCA can develop via transformation of mature hepatocytes and cholangiocytes, respectively. There is evidence that hepatic progenitor cells (HPCs), their intermediate states, or de-differentiated hepatocytes can form liver tumors with progenitor-like features, including mixed HCC-CCA, such as cholangiolocellular carcinoma (CLC). Mature hepatocytes can be also re-programmed into cells that closely resemble biliary epithelial cells and contribute to development of iCCA.

**Figure 4: Molecular biomarkers of HCC.** Genetic features and gene expression of the tumor or its surrounding microenvironment correlate with clinical and pathology features, etiology, and patient outcomes. The proliferation subclass is characterized by proliferation signaling pathways, which involve proteins such as MTOR, Notch, and TGFB and several gene expression signatures associated with poor outcomes of patients (such as the G3 and 5-gene signatures)<sup>97</sup>. The non-proliferation subclass is characterized by mutations in CTNNB1, the S3 gene expression signature, and the classical WNT signaling pathway. Specific mutations associated with etiology (smoking and aflatoxin B exposure) have also been described<sup>96</sup>. An expression pattern of 186 genes in the liver tissue surrounding the HCC can identify patients HCC at higher risk for tumor recurrence after resection<sup>103</sup>.



**Figure 5: Main characteristics of subclasses of iCCA.** Analyses of gene expression patterns have shown that iCCAs can be assigned to the proliferation or inflammation subclasses. The proliferation class is characterized by chromosome instability, activation of pathways related to cell cycle progression, mutations in oncogenes and shorter survival times of patients. Tumors of the inflammation subclass have gene expression patterns associated with activation of an immune response and less aggressive clinical behavior. FGFR2 fusion events are evenly distributed between these subclasses.

#### **ACKNOWLEDGMENTS**

The authors would like to thank Jill Gregory for her contribution in the design work of the figures.

## REFERENCES

1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2197-223.
2. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2016;2:16018.
3. Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. *Nat Rev Clin Oncol* 2015;12:436.
4. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2095-128.
5. Bosman FT, Carneiro Ft, World Health Organization., et al. WHO classification of tumours of the digestive system. Lyon: IARC, 2010.
6. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
7. Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. *Clin Gastroenterol Hepatol* 2015;13:2140-51.
8. Llovet JM, Villanueva A. Effect of HCV clearance with direct-acting antiviral agents on HCC. *Nat Rev Gastroenterol Hepatol* 2016 (in press).
9. **Reig M, Marino Z**, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol* 2016;65:719-26.
10. **Conti F, Buonfiglioli F**, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol* 2016;65:727-33.
11. Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. *J Hepatol* 2016;65:741-7.
12. Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. *Cancer Lett* 2009;286:9-14.
13. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. *J Hepatol* 2014;60:1268-89.
14. Moeini A, Sia D, Bardeesy N, et al. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. *Clin Cancer Res* 2016;22:291-300.
15. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. *J Hepatol* 2012;57:69-76.
16. Stanger BZ. Cellular homeostasis and repair in the mammalian liver. *Annu Rev Physiol* 2015;77:179-200.
17. Knouse KA, Wu J, Whittaker CA, et al. Single cell sequencing reveals low levels of aneuploidy across mammalian tissues. *Proc Natl Acad Sci U S A* 2014;111:13409-14.
18. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. *Semin Liver Dis* 2003;23:385-96.
19. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. *Nat Med* 2006;12:410-6.
20. Wang M, Xiao J, Jiang J, et al. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells. *Int J Cancer* 2011;128:1996-7.
21. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. *Oncogene* 2006;25:3818-22.

22. Singh S, Chakraborty S, Bonthu N, et al. Combined hepatocellular cholangiocarcinoma: a case report and review of literature. *Dig Dis Sci* 2013;58:2114-23.
23. Tanimizu N, Nakamura Y, Ichinohe N, et al. Hepatic biliary epithelial cells acquire epithelial integrity but lose plasticity to differentiate into hepatocytes in vitro during development. *J Cell Sci* 2013;126:5239-46.
24. Chen Y, Wong PP, Sjeklocha L, et al. Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. *Hepatology* 2012;55:563-74.
25. Tarlow BD, Pelz C, Naugler WE, et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. *Cell Stem Cell* 2014;15:605-18.
26. Guest RV, Boulter L, Kendall TJ, et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. *Cancer Res* 2014;74:1005-10.
27. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. *Cell Res* 2012;22:457-72.
28. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. *Nat Rev Cancer* 2003;3:895-902.
29. Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer. *Nat Rev Cancer* 2012;12:170-80.
30. **Barker N, Ridgway RA**, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 2009;457:608-11.
31. Zhu L, Gibson P, Curre DS, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. *Nature* 2009;457:603-7.
32. **Lapouge G, Youssef KK**, Vokaer B, et al. Identifying the cellular origin of squamous skin tumors. *Proc Natl Acad Sci U S A* 2011;108:7431-6.
33. Duncan AW, Dorrell C, Grompe M. Stem cells and liver regeneration. *Gastroenterology* 2009;137:466-81.
34. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. *Mech Dev* 2003;120:117-30.
35. Miyajima A, Tanaka M, Itoh T. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming. *Cell Stem Cell* 2014;14:561-74.
36. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. *Hepatology* 2004;39:1477-87.
37. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. *Hepatology* 2004;39:1739-45.
38. Turanyi E, Dezso K, Csomor J, et al. Immunohistochemical classification of ductular reactions in human liver. *Histopathology* 2010;57:607-14.
39. Peng N, Li L, Cai X, et al. Liver stem/progenitor cells in the canals of Hering: cellular origin of hepatocellular carcinoma with bile duct tumor thrombi? *Stem Cell Rev* 2010;6:579-84.
40. Lu WY, Bird TG, Boulter L, et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. *Nat Cell Biol* 2015;17:971-83.
41. Furuyama K, Kawaguchi Y, Akiyama H, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. *Nat Genet* 2011;43:34-41.
42. Espanol-Suner R, Carpentier R, Van Hul N, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. *Gastroenterology* 2012;143:1564-1575 e7.
43. Petersen BE, Grossbard B, Hatch H, et al. Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers. *Hepatology* 2003;37:632-40.

44. **Yanger K, Knigin D**, Zong Y, et al. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. *Cell Stem Cell* 2014;15:340-9.
45. Schaub JR, Malato Y, Gormond C, et al. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury. *Cell Rep* 2014;8:933-9.
46. Wang B, Zhao L, Fish M, et al. Self-renewing diploid Axin2(+) cells fuel homeostatic renewal of the liver. *Nature* 2015;524:180-5.
47. Suzuki A, Sekiya S, Buscher D, et al. Tbx3 controls the fate of hepatic progenitor cells in liver development by suppressing p19ARF expression. *Development* 2008;135:1589-95.
48. Font-Burgada J, Shalapour S, Ramaswamy S, et al. Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer. *Cell* 2015;162:766-79.
49. Zaret KS. Regenerative biology: Maintaining liver mass. *Nature* 2015;524:165-6.
50. Kitade M, Factor VM, Andersen JB, et al. Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. *Genes Dev* 2013;27:1706-17.
51. Chiba T, Zheng YW, Kita K, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. *Gastroenterology* 2007;133:937-50.
52. Tschaharganeh DF, Xue W, Calvisi DF, et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. *Cell* 2014;158:579-92.
53. Fitamant J, Kottakis F, Benhamouche S, et al. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. *Cell Rep* 2015.
54. Lu L, Li Y, Kim SM, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. *Proc Natl Acad Sci U S A* 2010;107:1437-42.
55. **Lee KP, Lee JH**, Kim TS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. *Proc Natl Acad Sci U S A* 2010;107:8248-53.
56. **Benhamouche S, Curto M**, Saotome I, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. *Genes Dev* 2010;24:1718-30.
57. Holczbauer A, Factor VM, Andersen JB, et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. *Gastroenterology* 2013;145:221-31.
58. Cardinale V, Wang Y, Carpino G, et al. The biliary tree--a reservoir of multipotent stem cells. *Nat Rev Gastroenterol Hepatol* 2012;9:231-40.
59. Cardinale V, Wang Y, Carpino G, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. *Hepatology* 2011;54:2159-72.
60. Torbenson M. Fibrolamellar carcinoma: 2012 update. *Scientifica (Cairo)* 2012;2012:743790.
61. **Villanueva A, Alsinet C, Yanger K**, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. *Gastroenterology* 2012;143:1660-1669 e7.
62. **Zender S, Nickeleit I, Wuestefeld T**, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. *Cancer Cell* 2013;23:784-95.
63. **Saha SK, Parachoniak CA**, Ghanta KS, et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. *Nature* 2014;513:110-4.
64. **Ikenoue T, Terakado Y**, Nakagawa H, et al. A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. *Sci Rep* 2016;6:23899.
65. Mu X, Espanol-Suner R, Mederacke I, et al. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. *J Clin Invest* 2015;125:3891-903.
66. **Shin S, Wangensteen KJ, Teta-Bissett M**, et al. Genetic Lineage Tracing Analysis of the Cell of Origin of Hepatotoxin-Induced Liver Tumors in Mice. *Hepatology* 2016.

67. Jors S, Jeliaskova P, Ringelhan M, et al. Lineage fate of ductular reactions in liver injury and carcinogenesis. *J Clin Invest* 2015;125:2445-57.
68. **He G, Dhar D, Nakagawa H**, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. *Cell* 2013;155:384-96.
69. Marquardt JU. Deconvolution of the cellular origin in hepatocellular carcinoma: Hepatocytes take the center stage. *Hepatology* 2016;64:1020-3.
70. Umemura A, He F, Taniguchi K, et al. p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells. *Cancer Cell* 2016.
71. **Yanger K, Zong Y**, Maggs LR, et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. *Genes Dev* 2013;27:719-24.
72. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. *J Clin Invest* 2012;122:3914-8.
73. Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. *J Clin Invest* 2012;122:2911-5.
74. Komuta M, Spee B, Vander Borgh S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. *Hepatology* 2008;47:1544-56.
75. **Hernandez-Gea V, Toffanin S**, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. *Gastroenterology* 2013;144:512-27.
76. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646-74.
77. Matter MS, Marquardt JU, Andersen JB, et al. Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. *Hepatology* 2016;63:1888-99.
78. Finkin S, Yuan D, Stein I, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. *Nat Immunol* 2015;16:1235-44.
79. **Lade A, Noon LA**, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. *Curr Opin Oncol* 2014;26:100-7.
80. Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. *Cancer Cell* 2014;26:549-64.
81. Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. *Nature* 2016;531:253-7.
82. Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. *Hepatology* 2015;61:1627-42.
83. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology* 2013;145:1215-29.
84. Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. *Hepatology* 2005;42:1329-38.
85. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology* 2013;144:829-40.
86. Kroemer G, Senovilla L, Galluzzi L, et al. Natural and therapy-induced immunosurveillance in breast cancer. *Nat Med* 2015;21:1128-38.
87. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2015;12:681-700.

88. Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. *Gut* 2015;64:842-8.
89. El-Khoueiry AB, Melero I, Crocenzi T, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. *J Clin Oncol* 33, 2015 (suppl; abstr LBA101) 2015.
90. Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. *Cancer Immunol Immunother* 2012;61:1019-31.
91. Bald T, Landsberg J, Lopez-Ramos D, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. *Cancer Discov* 2014;4:674-87.
92. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med* 2014;371:2189-99.
93. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. *J Clin Oncol* 2015;33:1974-82.
94. Sia D, Jiao Y, Martinez-Quetglas I, et al. Characterization of the immune class of hepatocellular carcinoma 10th ILCA Annual Conference. 9-11 September 2016. Vancouver, Canada (abstract O-007).
95. **Nakamura H, Arai Y, Totoki Y**, et al. Genomic spectra of biliary tract cancer. *Nat Genet* 2015;47:1003-10.
96. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. *J Hepatol* 2016.
97. Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. *Gastroenterology* 2015;149:1226-1239 e4.
98. Tovar V, Alsinet C, Villanueva A, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. *J Hepatol* 2010;52:550-9.
99. Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. *Gastroenterology* 2011;140:1501-12 e2.
100. **Nault JC, De Reynies A**, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. *Gastroenterology* 2013;145:176-87.
101. Toffanin S, Hoshida Y, Lachenmayer A, et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. *Gastroenterology* 2011;140:1618-28 e16.
102. **Villanueva A, Portela A**, Sayols S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. *Hepatology* 2015;61:1945-56.
103. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. *N Engl J Med* 2008;359:1995-2004.
104. Fuchs BC, **Hoshida Y, Fujii T**, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. *Hepatology* 2014;59:1577-90.
105. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. *Nature* 2013;500:415-21.
106. **Schulze K, Imbeaud S, Letouze E**, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nat Genet* 2015;47:505-11.
107. **Totoki Y, Tatsuno K, Covington KR**, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. *Nat Genet* 2014;46:1267-73.

108. **Fujimoto A, Furuta M, Totoki Y**, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. *Nat Genet* 2016;48:500-9.
109. **Sung WK, Zheng H, Li S**, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. *Nat Genet* 2012;44:765-9.
110. **Nault JC, Datta S, Imbeaud S**, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. *Nat Genet* 2015;47:1187-93.
111. **Shaw AT, Kim DW**, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-94.
112. Hagel M, Miduturu C, Sheets M, et al. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. *Cancer Discov* 2015;5:424-37.
113. **Huynh H, Hao HX**, Chan SL, et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. *Mol Cancer Ther* 2015;14:1224-35.
114. Zhu AX, Chen D, He W, et al. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. *J Hepatol* 2016;65:296-304.
115. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378-90.
116. Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival. PRESS RELEASE. <http://www.prnewswire.com/news-releases/phase-iii-trial-of-regorafenib-in-patients-with-unresectable-liver-cancer-meets-primary-endpoint-of-improving-overall-survival-300262856.html> 2016.
117. Sawey ET, Chanrion M, Cai C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. *Cancer Cell* 2011;19:347-58.
118. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 2010;17:1471-4.
119. Oishi N, Kumar MR, Roessler S, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. *Hepatology* 2012;56:1792-803.
120. **Boyault S, Rickman DS, de Reynies A**, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. *Hepatology* 2007;45:42-52.
121. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Res* 2009;69:7385-92.
122. Woo HG, Lee JH, Yoon JH, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. *Cancer Res* 2010;70:3034-41.
123. Andersen JB, Thorgeirsson SS. Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities. *Gastroenterology* 2013;144:687-90.
124. **Chan-On W, Nairismagi ML, Ong CK**, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nat Genet* 2013;45:1474-8.
125. **Jiao Y, Pawlik TM, Anders RA**, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nat Genet* 2013;45:1470-3.
126. Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nat Commun* 2015;6:6087.

127. Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. *Oncologist* 2014;19:235-42.
128. **Simbolo M, Fassan M, Ruzzenente A**, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. *Oncotarget* 2014;5:2839-52.
129. **Fujimoto A, Furuta M**, Shiraishi Y, et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. *Nat Commun* 2015;6:6120.
130. **Zou S, Li J, Zhou H**, et al. Mutational landscape of intrahepatic cholangiocarcinoma. *Nat Commun* 2014;5:5696.
131. Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. *PLoS One* 2014;9:e115383.
132. **Arai Y, Totoki Y, Hosoda F**, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. *Hepatology* 2014;59:1427-34.
133. **Borad MJ, Champion MD, Egan JB**, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. *PLoS Genet* 2014;10:e1004135.
134. Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. *Hum Pathol* 2014;45:1630-8.
135. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discov* 2013;3:636-47.
136. Javle M, Shroff R, Zhu A, et al. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. *Clin Oncol* 2016;34.
137. Mazzaferro V, Shaib W, Rimassa L, et al. ARQ 087, an oral Pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA). <https://globenewswire.com/news-release/2016/06/30/852679/0/en/ArQule-Presents-Preliminary-Clinical-Data-for-ARQ-087-Demonstrating-Evidence-of-Anticancer-Activity-in-Intrahepatic-Cholangiocarcinoma-at-the-ESMO-18th-World-Congress-on-Gastrointe.html> 2016.
138. Cornella H, Alsinet C, Sayols S, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. *Gastroenterology* 2015;148:806-18 e10.
139. **Honeyman JN, Simon EP, Robine N**, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. *Science* 2014;343:1010-4.
140. Simon EP, Freije CA, Farber BA, et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. *Proc Natl Acad Sci U S A* 2015;112:E5916-25.
141. **Cairo S, Armengol C**, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. *Cancer Cell* 2008;14:471-84.
142. Nicolle D, Fabre M, Simon-Coma M, et al. Patient-derived xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. *Hepatology* 2016.
143. Bissig-Choisat B, Kettlun-Leyton C, Legras XD, et al. Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. *J Hepatol* 2016;65:325-33.
144. Theise ND, Nakashima O, Park YN. Combined hepatocellular-cholangiocarcinoma. In: osman FT, Carneiro F H, RH TN, eds. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC; 2010:225–227.



145. Coulouarn C, Cavard C, Rubbia-Brandt L, et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFbeta signaling pathways. *Carcinogenesis* 2012;33:1791-6.
146. Moeini A, Sia D, Zhang Z, et al. Mixed hepatocellular-cholangiocarcinoma tumors: stem-cell subtype and cholangiolocellular carcinoma are unique molecular entities. *Hepatology* 2015;62, Number 1 (SUPPL): 342A.
147. **Gerlinger M, Rowan AJ, Horswell S**, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med* 2012;366:883-92.
148. Alizadeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. *Nat Med* 2015;21:846-53.
149. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351:2817-26.
150. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J Clin Oncol* 2009;27:2091-6.
151. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012;56:908-43.
152. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. *J Natl Cancer Inst* 1996;88:1456-66.
153. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). *J Natl Cancer Inst* 2005;97:1180-4.
154. Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. *BMJ* 2013;346:e5595.
155. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst* 2009;101:1446-52.
156. Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med* 2015;373:2005-14.
157. Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. *Clin Cancer Res* 2012;18:2290-300.
158. Hoshida Y, Villanueva A, Sangiovanni A, et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. *Gastroenterology* 2013;144:1024-30.
159. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. *N Engl J Med* 2009;361:1437-47.
160. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. *Cancer Res* 2008;68:1451-61.
161. **Budhu A, Jia HL**, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. *Hepatology* 2008;47:897-907.
162. **Valle J, Wasan H**, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010;362:1273-81.
163. Gu MJ, Choi JH. Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma. *J Clin Pathol* 2014;67:229-34.
164. **Huang XY, Zhang C, Cai JB**, et al. Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients. *PLoS One* 2014;9:e96860.
165. Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. *Hepatology* 2013;58:1992-2000.

166. Plieskatt J, Rinaldi G, Feng Y, et al. A microRNA profile associated with *Opisthorchis viverrini*-induced cholangiocarcinoma in tissue and plasma. *BMC Cancer* 2015;15:309.
167. Li L, Masica D, Ishida M, et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. *Hepatology* 2014;60:896-907.
168. **Zhang MY, Li SH**, Huang GL, et al. Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. *BMC Cancer* 2015;15:64.
169. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. *N Engl J Med* 2014;371:2140-1.
170. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. *N Engl J Med* 2009;361:98-9.
171. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. *Cancer Res* 2005;65:6063-9.
172. **Ruzzenente A, Fassan M**, Conci S, et al. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. *Ann Surg Oncol* 2016;23:1699-707.
173. **Wang P, Dong Q**, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. *Oncogene* 2013;32:3091-100.
174. Labgaa I, Villanueva A. Liquid biopsy in liver cancer. *Discov Med* 2015;19:263-73.
175. He J, Lu H, Zou Q, et al. Regeneration of liver after extreme hepatocyte loss occurs mainly via biliary transdifferentiation in zebrafish. *Gastroenterology* 2014;146:789-800 e8.
176. Sangro B, Park JW, De la Cruz CM, et al. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. *J Clin Oncol* 34, 2016 (suppl; abstr TPS4147).

Notes: Author names in bold designate shared co-first authorship

**Table 1.** Experimental models supporting the different hypotheses regarding the cell of origin in primary liver cancers

Hypothesis tested	Method	Animal models	Altered pathway	Tumor Type	Proposed cell of origin	Reference
<i>HPC/oval cells as cell of origin</i>	Clonal analyses	-	BMI1, WNT	mixed HCC-iCCA	HPCs	51
	GEMM	Sav1fl/fl, mst1fl/fl, and mst2fl/fl	HIPPO	HCC, iCCA	oval cells	54
	GEMM	WW45flox/floxAlbumin-Cre	HIPPO	mixed HCC-iCCA	oval cells	55
	Multilineage differentiation	-	H-Ras, SV40LT	HCC, iCCA	HPC, hepatoblasts, hepatocytes	57
	GEMM	Alb-Cre;Nf2 <sup>lox/lox</sup>	NF2	HCC, iCCA, mixed	oval cells	56
	GEMM	Notch1C::AlbCre	NOTCH	iCCA	HPCs	62
	GEMM	Alb-Cre;LSL-IDH2R172K;LSL-KrasG12D	IDH, KRAS	iCCA	hepatoblasts	63
	GEMM	LSL-KrasG12D -Ptenflox	KRAS, PTEN	iCCA	hepatoblasts, cholangiocytes	64
<i>Hepatocytes as cell of origin</i>	GEMM	AlfpCre <sup>+</sup> Trp53 <sup>Δ2-10/Δ2-10</sup>	TP53, WNT	HCC	hepatocytes-derived HPC	52
	GEMM	AlfpCre <sup>+</sup> Trp53 <sup>Δ2-10/Δ2-10</sup>	TP53, NOTCH	iCCA	hepatocytes-derived HPC	52
	GEMM	(Mst1/Mst2 DKO, YAP KO, DKO Yap+/-, and tTKO)	HIPPO	HCC	hepatocytes-derived HPC/oval cells	53
	Multilineage differentiation	-	H-Ras, SV40LT	HCC, iCCA	HPC, hepatoblasts, hepatocytes	57
	lineage-tracing system	liver injury (BDL, DDC, MDA, CDE); GEMM (Mdr2 <sup>-/-</sup> )	MDR	HCC	hepatocytes	67
	lineage-tracing system	liver injury (DEN); GEMM (Mdr2 <sup>-/-</sup> ; PTEN <sup>-/-</sup> )	MDR, PTEN	HCC	hepatocytes	65
	lineage-tracing system	DEN + TAA	-	HCC, HPA	hepatocytes	66
	GEMM	Tsc1/Sqstm1 <sup>Δhep</sup> and Sqstm1 <sup>Δhep</sup> /MUP	p62	HCC	hepatocytes	70
	lineage-tracing system	Alb-CreERT2;R26RlacZ/+ and CK19-CreERT2;R26RlacZ/+	NOTCH	iCCA	hepatocytes	72
lineage-tracing system	hydrodynamic tail injection	NOTCH, AKT	iCCA	hepatocytes-derived biliary-like cells	73	
<i>Cholangiocytes as cell of origin</i>	lineage-tracing system	Liver injury (TAA) and CK19CreERT <sup>eYFPp53<sup>fl/fl</sup></sup>	TP53	iCCA	cholangiocytes	26
	GEMM	LSL-KrasG12D -Ptenflox	KRAS, PTEN	iCCA	hepatoblasts, cholangiocytes	64


**Abbreviations:** HPC, Hepatic progenitor cells; GEMM: genetically engineered mouse model; HCC, hepatocellular carcinoma; HPA, hepatocellular adenoma; iCCA, intrahepatic cholangiocarcinoma; mixed HCC-iCCA, mixed hepatocellular-cholangiocarcinoma; KO, knock-out; DKO, double knock-out; TKO, triple knock-out; DEN, N-nitrosodiethylamine; TAA, Thioacetamide; BDL, bile duct ligation; MDA, methylene dianiline; CDE, choline-deficient ethionine-supplemented; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine.


**Table 2.** Prognostic signatures in primary liver cancer


Signature	Cohort (etiology)	Number of patients tested Training/Validation set	Clinical endpoint	REMARK recommendations	Level of evidence (Simon et al. JNCI 2009)	Reference
<b>Hepatocellular Carcinoma</b>						
<i>mRNA-based</i>						
5-gene signature	HCC (Alcohol, HCV, HBV)	189/434	survival	OK	C	100
EpCAM-signature	HCC (HBV)	40/238	survival	OK	C	160
186-gene signature (adjacent tissue)	HCC (HCV)	82/441	survival, HCC development	OK	C	103, 158
<i>miRNA based</i>						
20-miRNA signature	HCC (HBV)	131/110	venous metastasis, survival	OK	C	161
Down-regulation miR-26a	HCC (HBV)	241/214	survival	OK	C	159
<i>DNA methylation</i>						
36 CpG DNA methylation signature	HCC (HCV)	221/83	survival	OK	C	102
<i>Protein markers (Plasma)</i>						
Ang2, VEGF	HCC (HCV)	491	survival	OK	B	157
<b>Cholangiocarcinoma</b>						
<i>mRNA-based</i>						
poor prognosis/proliferation class	iCCA	119/104	survival and recurrence	further validation required	C	85
poor prognosis group	iCCA and eCCA	52/52	survival and recurrence	further validation required	C	123
Stem cell-like subtype	iCCA and mixed HCC-CCA	23/68	survival	further validation required	C	119


**Abbreviations:** HCC, hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma; mixed HCC-iCCA, mixed hepatocellular-cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma.

Figure 1











## iCCA Molecular Classes

Characteristics	Proliferation Class	Inflammation Class
<b>Subtype</b>	Progenitor-like iCCA	
<b>Signalling Pathways</b>	KRAS/RAF/ERK, IGF1R, EGFR, NOTCH, HER2, MET, PI3K/AKT/mTOR	Inflammatory pathways (Interleukins/chemokines), STAT3 activation
<b>Prognostic Signatures</b>	Poor prognostic signatures (i.e. G3, S1-2, Cluster A, stroma, iCCA-like HCC) Stem cell like iCCA	
<b>DNA Methylation</b>	Hyper-methylation	
<b>Oncogenic Mutations</b>	<i>KRAS, BRAF, EGFR</i> <i>IDH1/2</i> Chromatin remodelling genes ( <i>ARID1A, BAP1, PBMR1</i> ), <i>TP53</i>	
<b>Structural Aberrations</b>	Chr 11q13 amplif. ( <i>CCND1, FGF19</i> ) Chr14q22.1 ( <i>SAV1</i> ) Focal deletion <i>FGFR2</i> translocations	
<b>Clinical Features</b>	Intra-neural invasion Moderate/poorly differentiated Poor prognosis (survival/recurrence)	Well differentiated Good prognosis